Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Core Insights - Apellis Pharmaceuticals (NASDAQ: APLS) has faced significant challenges over the past two years, including safety concerns regarding its product Syfovre, which have since been largely resolved, and a rejection from the European Medicines Agency [2]. Company Overview - Apellis Pharmaceuticals is currently navigating a recovery phase after overcoming a safety scare related to Syfovre, which has been a critical product for the company [2]. Investment Focus - The Growth Stock Forum, which covers Apellis Pharmaceuticals, emphasizes attractive risk/reward situations and closely tracks a model portfolio of 15-20 stocks, along with a top picks list of up to 10 stocks expected to perform well in the current calendar year [1].